Loading
Incidental gallbladder cancer is cancer the pathologist finds in a gallbladder removed for gallstones or inflammation, when nobody suspected it. It is the commonest way this cancer is found early enough to cure. Whether a second operation is needed depends on how deep the tumour went: none for the earliest layers, a radical operation at a specialist centre for T1b or deeper.
Between one in 400 and one in 110 gallbladders removed for presumed benign disease contains a cancer (0.25 to 0.89 percent; Soreide 2019), and the share rises steeply with age (0.08 percent under 60 versus 0.67 percent over 60 in Denmark, where every specimen is examined; the surgeon had noted macroscopic changes in 27 of 28 cancers, Lerche-Jorgensen 2025). About half are pT2 and a third pT1. Patients whose cancer is confined to the mucosa (T1a or less) have five-year survival of up to 100 percent after the cholecystectomy alone; for T1b or deeper tumours re-resection is recommended, though its type, extent and timing remain debated (Soreide 2019; AHPBA consensus, Aloia 2015). Ten US academic centres found re-resection between 4 and 8 weeks after the first operation gave the longest survival (median 40.4 months, against 17.4 months under 4 weeks and 22.4 months over 8 weeks), the interval allowing new CT or MRI and PET-CT, which can show residual or distant disease and prevent a futile operation (Ethun 2017; Soreide 2019). Perforation of the gallbladder at the first operation raises the risk of dissemination, and the risk of peritoneal spread rises with each T category. Port-site metastases occurred in 18.6 percent of laparoscopic cases before 2000 and 10.3 percent since (Berger-Richardson 2017); routine excision of the port sites does not improve survival (Soreide 2019). Routine staging laparoscopy before re-resection is not needed for every stage. Adjuvant chemotherapy after re-resection is poorly documented and probably underused (Soreide 2019).
Getting patients to the right place is the weak link: in 27 Dutch secondary hospitals only 53.9 percent of 243 patients eligible for re-resection (pT1b to pT3, M0) were referred to a tertiary centre, and in nearly half of the non-referred the reason was not documented (van Dooren 2024). In the UK the specialist hepatobiliary multidisciplinary team is the route; two UK units have described their approach to suspected cancer, using intraoperative frozen section to decide on extending surgery at the first operation (Chan 2022, Liverpool; Banh 2024, London). The UK pathway page carries referral detail; this page covers what the finding means.
0.25 to 0.89 percent of all cholecystectomy specimens in the series reviewed by Soreide (2019); 0.29 percent of 9,698 in a Danish department, 0.08 percent under 60 and 0.67 percent over 60 (Lerche-Jorgensen 2025). Roa and colleagues say most gallbladder cancers are found this way.
Most pancreatic cancers arise in the head next to the bile duct, which is why jaundice is the presenting sign; bile duct cancers are named by where along the tree they sit.
Same organ: Glucagonoma, VIPoma, Somatostatinoma, Pancreatic ductal adenocarcinoma, Biliary tract cancer (cholangiocarcinoma), Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma (perihilar and distal), Biliary tract cancer (all types), Neuroendocrine tumours, Pancreatic neuroendocrine tumours, Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma, Gallbladder cancer, Gallbladder adenocarcinoma, Papillary carcinoma of the gallbladder, Mucinous carcinoma of the gallbladder, Adenosquamous and squamous carcinoma of the gallbladder, Neuroendocrine carcinoma of the gallbladder, Carcinoma in situ and dysplasia of the gallbladder, Cystic duct carcinoma, Ampullary cancer (ampulla of Vater), Resectable pancreatic ductal adenocarcinoma, Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Pancreatic acinar cell carcinoma, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatoblastoma, Adenosquamous carcinoma of the pancreas, Colloid (mucinous non-cystic) carcinoma of the pancreas, Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma), Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma), Solid pseudopapillary neoplasm of the pancreas
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
No further surgery; the simple cholecystectomy is treatment enough.
Referral to a hepatobiliary centre; interval CT or MRI and PET-CT; radical cholecystectomy (liver bed plus portal lymphadenectomy) at 4 to 8 weeks, with bile duct resection only for a positive cystic duct margin; port sites not routinely excised; adjuvant capecitabine after.
Systemic treatment as for advanced gallbladder cancer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
This is the UK baseline for the incidental cancer pathway: a re-resection rate well above the Dutch registry's 24 percent, with the same selection caveat. The abstract leaves out the histology, referral and timing detail; the full paper holds it.
It softens the Ethun four-to-eight-week rule: timing within the range that services can deliver probably matters less than completing the operation at all and doing it with the liver bed and nodes cleared.
The rationale for OPT-IN and GAIN in one place. Until OPT-IN reports in 2028 the neoadjuvant approach for incidental cancer remains a reasoned choice rather than a proven one.
The best single starting point for a clinician or researcher new to the disease, written by the groups running the Chilean and Indian cohorts; its list of unmet needs is the skeleton of the ideas section on this page.
Six per thousand is the number behind the debate on routine versus selective histology of gallbladder specimens: applied to a national cholecystectomy volume it predicts a few hundred unsuspected cancers a year in a country the size of England.
GAIN closed in October 2024 with 68 participants according to ClinicalTrials.gov, one fifth of its target: the clearest example of how hard it is to run a randomised surgical trial in incidental gallbladder cancer, and why OPT-IN's result matters.
A whole-country picture of the gap between guideline and practice: three quarters of eligible patients never reached the second operation. The survival difference is confounded by selection but the residual disease rate is not.
The UK-authored summary that most NHS hepatobiliary units work from; it names the open questions (type, extent and timing of re-resection; adjuvant chemotherapy) that the trials in this roadmap are trying to answer.
Query for this cancer: (TITLE:"Incidental gallbladder cancer" OR ABSTRACT:"Incidental gallbladder cancer" OR TITLE:"found after cholecystectomy" OR ABSTRACT:"found after cholecystectomy" OR TITLE:"Incidentally discovered gallbladder cancer" OR ABSTRACT:"Incidentally discovered gallbladder cancer" OR TITLE:"Unsuspected gallbladder cancer" OR ABSTRACT:"Unsuspected gallbladder cancer" OR TITLE:"Occult gallbladder cancer" OR ABSTRACT:"Occult gallbladder cancer" OR TITLE:"IGBC" OR ABSTRACT:"IGBC") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Incidental gallbladder cancer (found after cholecystectomy), not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Answer a few questions from a report and read the guideline statement that applies, quoted word for word with its source. Educational aids to prepare for an appointment, not advice.
Bleeding that does not stop by itself, bleeding from more than one site, or new bruising in several places or one large area.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
Immunotherapy can attack hormone-producing glands: most often the thyroid (usually ending in an under-active thyroid needing lifelong tablets), and less often the pituitary (hypophysitis) or adrenal glands, which can be life-threatening if missed.
The bowel cancer regimens share low blood counts, tiredness, sickness and a sore mouth. Oxaliplatin adds cold-triggered tingling, irinotecan adds early and late diarrhoea, capecitabine adds hand-foot syndrome and needs a DPD test first, and cetuximab or panitumumab add an acne-like rash and low magnesium. The rule for all of them: ring the 24-hour number rather than wait.
See all on the product pages:CapecitabineDurvalumabGemcitabine + cisplatinPembrolizumab·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Incidental gallbladder cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.